ACADIA PHARMACEUTICALS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.1B | $957.8M | $726.4M | $517.2M | $484.1M |
| Cost of revenue | $89.0M | $81.8M | $41.6M | $10.2M | $19.1M |
| Gross profit | — | — | $684.8M | $507.1M | $473.3M |
| Selling, general & administrative | $548.9M | $488.4M | $406.6M | $369.1M | $396.0M |
| Research and development | $328.8M | $303.2M | $351.6M | $361.6M | $239.4M |
| Operating income | $104.8M | $230.8M | -$73.4M | -$223.6M | -$170.4M |
| Pretax income | $138.9M | $258.1M | -$51.0M | -$213.4M | -$167.5M |
| Income tax expense | -$252.1M | $31.6M | $10.2M | $2.5M | $351,000 |
| Net income | $391.0M | $226.5M | -$61.3M | -$216.0M | -$167.9M |
| Balance Sheet | |||||
| Cash and equivalents | $177.7M | $319.6M | $188.7M | $114.8M | $147.4M |
| Current assets | $1.1B | $938.3M | $616.1M | $507.9M | $617.8M |
| Total assets | $1.6B | $1.2B | $749.0M | $587.8M | $700.1M |
| Current liabilities | $277.1M | $394.9M | $254.3M | $125.6M | $96.1M |
| Total liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M |
| Stockholders' equity | $1.2B | $732.8M | $431.8M | $400.4M | $540.9M |
| Cash Flow Statement | |||||
| Cash from operations | $109.8M | $157.7M | $16.7M | -$114.0M | -$125.7M |
| Depreciation and amortization | $871,000 | $920,000 | $1.5M | $2.0M | $2.2M |
| Stock-based compensation | $52.1M | $67.0M | $66.4M | $68.2M | $63.6M |
| Capital expenditure | $4.7M | $523,000 | $50,000 | $0 | $1.1M |
| Free cash flow | $105.1M | $157.2M | $16.7M | -$114.0M | -$126.8M |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 171.2M · Free float 48.4%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.